Trial reportIntensive care medicine2026
Early high-dose vitamin C for out-of-hospital cardiac arrest: the VITaCCA randomized clinical trial.
Trial report in Intensive care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03509662 (Early High-dose Vitamin C in Post-cardiac Arrest Syndrome), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early High-dose Vitamin C in Post-cardiac Arrest Syndrome
Who cites it
2 citing papers in PubMed.
- Steroid, thiamine, and ascorbic acid for comatose out-of-hospital cardiac arrest survivors (STAR): a randomised, placebo-controlled, phase 2 trial.EClinicalMedicine · 2026Article
- Vitamin C in acute critical illness: don't confuse pharmacotherapy and nutrition!Intensive care medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundBesides temperature management, there is currently no effective therapy to decrease the burden of post-cardiac arrest syndrome. The pleiotropic effects of vitamin C may improve clinical outcome. PURPOSE: This trial investigated whether early administration of 3 g or 10 g intravenous vitamin C attenuated organ dysfunction post-cardiac arrest.
methodsIn this double-blind, multi-center, phase 2 trial, comatose adults resuscitated from shockable out-of-hospital cardiac arrest randomly received intravenously placebo, supplementary (3 g) or supraphysiological dose (10 g) vitamin C daily for 96 h. The primary endpoint was the 96 h change in the resuscitation-sequential organ failure assessment (R-SOFA) score. Secondary endpoints included neurological outcome, myocardial injury, vasopressor- and ventilator-free days, renal function, ICU-acquired weakness, delirium, length of ICU and hospital stay, and 28- and 180-day mortality.
results273 patients (93 on placebo, 91 on 3 g and 89 on 10 g) were included in the primary analysis. Mean (SD) change in R-SOFA score at 96 h was - 3.2 (5.7) in the placebo group, - 2.3 (7.4) in the 3 g group, and - 0.8 (7.6) in the 10 g group (p = 0.04 for overall difference). 10 g vitamin C resulted in 2.5 points less improvement in R-SOFA score compared with placebo (95% CI 0.5-4.5; p = 0.01), and 1.6 points less improvement compared with 3 g vitamin C (95% CI - 0.4 to 3.6; p = 0.12). Vitamin C 10 g led to higher troponin T release, worse renal function and worse neurological outcomes.
conclusionIn out-of-hospital cardiac arrest patients, intravenous vitamin C did not reduce organ dysfunction at 96 h, but even worsened organ function outcomes in the 10 g group.
trial registrationNCT03509662.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.